Novel Approach to Continuation of Elective Procedures in People at Risk for Sodium–Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Ketoacidosis.
- Resource Type
- Article
- Authors
- Verdone, Matthew; Bauman, Jonathan; Iversen, Esben; Schulman-Rosenbaum, Rifka; Antonacci, Anthony; Leffe, Sabatino; Simpson, Joseph; Harris, Yael Tobi; Marino, Joseph
- Source
- Diabetes Spectrum; Spring2024, Vol. 37 Issue 2, p165-169, 5p
- Subject
- RISK assessment
METFORMIN
EMPAGLIFLOZIN
ENZYME inhibitors
LAXATIVES
DIABETIC acidosis
HYPOGLYCEMIC agents
GLIPIZIDE
PREOPERATIVE care
KETONES
PROPOFOL
INTRAVENOUS therapy
ELECTIVE surgery
SODIUM-glucose cotransporter 2 inhibitors
TYPE 2 diabetes
TOTAL knee replacement
OSTEOARTHRITIS
COLONOSCOPY
DISEASE risk factors
- Language
- ISSN
- 10409165
The article presents a study which examined the impact of a simple algorithm piloted for evaluation of peri-procedural diabetic ketoacidosis (DKA) risk in cases where individuals inadvertently continue their sodium-glucose cotransporter 2 (SGLT2) inhibitor in the days before an elective procedure. It presents cases of common elective procedures that would have been canceled because of inadvertent SGL2 inhibitor use but were allowed to continue based on algorithm.